Skip to main content
. 2016 Jul 22;65(9):1099–1111. doi: 10.1007/s00262-016-1872-z

Fig. 2.

Fig. 2

Erythema at the injection site as a treatment-related prognostic factor for OS in the histological subtypes. a Kaplan–Meier plots of the OS times for all 260 patients with or without ≥30-mm erythema from the time of the first DC vaccine. b Kaplan–Meier plots of the OS times of patients with adenocarcinoma (n = 206, left) and those with other subtypes (n = 51) with and without ≥30-mm erythema from the time of first DC vaccine (P < 0.001 and P = 0.041, respectively)